JPMorgan Chase & Co. Issues Pessimistic Forecast for Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price reduced by equities research analysts at JPMorgan Chase & Co. from $11.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 194.99% from the stock’s previous close.

RXRX has been the subject of several other reports. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Finally, Bank of America lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.20.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $3.39 on Thursday. Recursion Pharmaceuticals has a 52-week low of $2.80 and a 52-week high of $7.18. The firm has a market capitalization of $1.79 billion, a PE ratio of -2.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50. The business’s 50-day simple moving average is $3.40 and its 200 day simple moving average is $4.20.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. The firm had revenue of $35.54 million during the quarter, compared to the consensus estimate of $24.56 million. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business’s revenue was up 671.7% compared to the same quarter last year. During the same period last year, the company earned ($0.53) earnings per share. As a group, sell-side analysts expect that Recursion Pharmaceuticals will post -0.93 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 13,426 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the transaction, the chief financial officer owned 1,195,349 shares in the company, valued at $3,681,674.92. This trade represents a 1.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the completion of the transaction, the director directly owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This represents a 3.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 299,680 shares of company stock valued at $1,180,121. 8.43% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. 180 Wealth Advisors LLC raised its stake in Recursion Pharmaceuticals by 82.1% in the first quarter. 180 Wealth Advisors LLC now owns 169,682 shares of the company’s stock valued at $521,000 after purchasing an additional 76,481 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after buying an additional 5,156 shares in the last quarter. Cherry Creek Investment Advisors Inc. grew its stake in Recursion Pharmaceuticals by 5.8% during the first quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock worth $217,000 after buying an additional 3,859 shares in the last quarter. Axxcess Wealth Management LLC increased its holdings in Recursion Pharmaceuticals by 16.6% in the 1st quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock valued at $115,000 after buying an additional 5,338 shares during the period. Finally, R Squared Ltd raised its position in shares of Recursion Pharmaceuticals by 52.3% in the 1st quarter. R Squared Ltd now owns 32,363 shares of the company’s stock valued at $99,000 after buying an additional 11,118 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.